Cargando…

Immunogenicity of panitumumab in combination chemotherapy clinical trials

BACKGROUND: Panitumumab is a fully human antibody against the epidermal growth factor receptor that is indicated for the treatment of metastatic colorectal cancer (mCRC) after disease progression on standard chemotherapy. The purpose of this analysis was to examine the immunogenicity of panitumumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weeraratne, Dohan, Chen, Alin, Pennucci, Jason J, Wu, Chi-Yuan, Zhang, Kathy, Wright, Jacqueline, Pérez-Ruixo, Juan José, Yang, Bing-Bing, Kaliyaperumal, Arunan, Gupta, Shalini, Swanson, Steven J, Chirmule, Narendra, Starcevic, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231982/ https://www.ncbi.nlm.nih.gov/pubmed/22070868 http://dx.doi.org/10.1186/1472-6904-11-17

Ejemplares similares

Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects
por: Jawa, Vibha, et al.
Publicado: (2010)

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
por: Kuriakose, Anshu, et al.
Publicado: (2016)

Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
por: Sauna, Zuben E., et al.
Publicado: (2023)

Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen
por: Al-asadi, Osamah, et al.
Publicado: (2018)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease
por: Krens, L. L., et al.
Publicado: (2017)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
por: Freeman, Daniel J, et al.
Publicado: (2012)

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
por: Smyth, Elizabeth C, et al.
Publicado: (2021)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Fluorouracil/oxaliplatin/panitumumab: Lack of efficacy: case report
Publicado: (2022)

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab
por: Odom, Dawn, et al.
Publicado: (2010)

A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report
por: Sonoda, Hiromichi, et al.
Publicado: (2014)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency
por: Tamura, Hotaka, et al.
Publicado: (2021)

Fluorescence-guided craniotomy of glioblastoma using panitumumab-IRDye800
por: Zhou, Quan, et al.
Publicado: (2022)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma
por: Halfdanarson, Thorvardur R, et al.
Publicado: (2022)

Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report
por: Tomizawa, Kenji, et al.
Publicado: (2017)

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
por: Raimondi, A., et al.
Publicado: (2021)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx, Jeroen J M A, et al.
Publicado: (2020)

Post-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms
por: Walsh, Robin E., et al.
Publicado: (2020)

A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
por: Kaur, Primal, et al.
Publicado: (2017)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Panitumumab-Induced Acneiform Rash in a Patient with Metastatic Colon Adenocarcinoma
por: Martins-Filho, Paulo Ricardo Saquete, et al.
Publicado: (2013)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
por: Watanabe, Shoichi, et al.
Publicado: (2017)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
por: Liao, Michael Z, et al.
Publicado: (2020)

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer
por: Domenico, Ciliberto, et al.
Publicado: (2019)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
por: García-Foncillas, Jesús, et al.
Publicado: (2019)

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Williams, Kerry J, et al.
Publicado: (2009)

Biopharmaceutical Industry Capability Building in India: Report from a Symposium
por: Uppal, Annu, et al.
Publicado: (2021)

A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention
por: Gopallawa, Indiwari, et al.
Publicado: (2023)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1gs9guh1eqvchv9vmlfejtlfjp